Current Bioactive Compounds

Current Bioactive Compounds

Editor-in-Chief

ISSN (Print): 1573-4072
ISSN (Online): 1875-6646

Back Subscribe
Research Article

Neuropharmacological Evaluation of Betaine against Parkinson’s Disease Rat Model

Author(s): Satinder Kaur, Navneet Khurana*, Md. Sadique Hussain, Rajesh Kumar, Gurvinder Singh, Ravi Kumar Dhawan, Mudasir Maqbool Bhat and Neha Sharma

Volume 21, Issue 10, 2025

Published on: 18 December, 2024

Article ID: e15734072327534

Pages: 15

DOI: 10.2174/0115734072327534241203055525

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Introduction: This study aimed at evaluating the neuropharmacological impacts of betaine, a natural compound known for its antioxidant properties, in a rat model of Parkinson’s disease induced by rotenone.

Methods: Male Wistar rats were separated into various groups and administered betaine at two different doses (10 mg/kg and 20 mg/kg orally), in addition to rotenone (2 mg/kg subcutaneously), for 35 days.

Results: Various parameters were analyzed to determine the effectiveness of betaine. After receiving rotenone, the subjects displayed various behavioral alterations such as catalepsy, delayed beam walk, postural instability, unusual movement patterns, reduced weight, altered rearing behavior, impaired muscle coordination, decreased locomotor activity, and weakened grip strength. Interestingly, these effects were notably alleviated when betaine was given alongside. Betaine demonstrated a reduction in rotenone-induced oxidative stress by lowering levels of thiobarbituric acid reactive substances (TBARS) and superoxide anion generation (SAG), while increasing levels of catalase (CAT) and glutathione (GSH) in the cerebrum and midbrain regions. Moreover, betaine helped alleviate the reduction in dopamine (DA) levels caused by rotenone-induced neurodegeneration. In general, the protective impact of betaine against rotenone-induced PD symptoms outperformed the typical treatment with Levodopa+Carbidopa (L+C), especially at the higher dosage of 20 mg/kg.

Conclusion: These results indicate that betaine shows potential as a therapeutic option for PD because of its antioxidant properties.

Keywords: Parkinson’s disease, rotenone, betaine, oxidative stress, neuropharmacological impacts, antioxidant properties.

Graphical Abstract

[1]
Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem., 1992, 59(5), 1609-1623.
[http://dx.doi.org/10.1111/j.1471-4159.1992.tb10990.x] [PMID: 1402908]
[2]
Olanow, CW Oxidation reactions in Parkinson’s disease. Neurology, 1990, 40(10)(Suppl. 3), 32-37.
[3]
Olanow, C.W. A radical hypothesis for neurodegeneration. Trends Neurosci., 1993, 16(11), 439-444.
[http://dx.doi.org/10.1016/0166-2236(93)90070-3] [PMID: 7507613]
[4]
Trist, B.G.; Hare, D.J.; Double, K.L. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell, 2019, 18(6), e13031.
[http://dx.doi.org/10.1111/acel.13031] [PMID: 31432604]
[5]
Jenner, P.; Olanow, C.W. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology, 1996, 47(6_suppl_3)(Suppl. 3), S161-S170.
[http://dx.doi.org/10.1212/WNL.47.6_Suppl_3.161S] [PMID: 8959985]
[6]
Berg, D.; Gerlach, M.; Youdim, M.B.H.; Double, K.L.; Zecca, L.; Riederer, P.; Becker, G. Brain iron pathways and their relevance to Parkinson’s disease. J. Neurochem., 2001, 79(2), 225-236.
[http://dx.doi.org/10.1046/j.1471-4159.2001.00608.x] [PMID: 11677250]
[7]
Castellani, R.J.; Perry, G.; Siedlak, S.L.; Nunomura, A.; Shimohama, S.; Zhang, J.; Montine, T.; Sayre, L.M.; Smith, M.A. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett., 2002, 319(1), 25-28.
[http://dx.doi.org/10.1016/S0304-3940(01)02514-9] [PMID: 11814645]
[8]
Jenner, P.; Olanow, C.W. Understanding cell death in Parkinson’s disease. Ann. Neurol., 1998, 44(3)(Suppl. 1), S72-S84.
[PMID: 9749577]
[9]
Buneeva, O.; Medvedev, A. Atypical Ubiquitination and Parkinson’s Disease. Int. J. Mol. Sci., 2022, 23(7), 3705.
[http://dx.doi.org/10.3390/ijms23073705] [PMID: 35409068]
[10]
Dexter, D.T.; Carter, C.J.; Wells, F.R.; Javoy-Agid, F.; Agid, Y.; Lees, A.; Jenner, P.; Marsden, C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J. Neurochem., 1989, 52(2), 381-389.
[http://dx.doi.org/10.1111/j.1471-4159.1989.tb09133.x] [PMID: 2911023]
[11]
Bové, J.; Prou, D.; Perier, C.; Przedborski, S. Toxin-induced models of Parkinson’s disease. NeuroRx, 2005, 2(3), 484-494.
[http://dx.doi.org/10.1602/neurorx.2.3.484]
[12]
Kotake, Y.; Ohta, S. MPP+ analogs acting on mitochondria and inducing neuro-degeneration. Curr. Med. Chem., 2003, 10(23), 2507-2516.
[http://dx.doi.org/10.2174/0929867033456558] [PMID: 14529466]
[13]
Uversky, V.N. Neurotoxicant-induced animal models of Parkinson?s disease: Understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res., 2004, 318(1), 225-241.
[http://dx.doi.org/10.1007/s00441-004-0937-z] [PMID: 15258850]
[14]
Kip, E.; Parr-Brownlie, L.C. Healthy lifestyles and wellbeing reduce neuroinflammation and prevent neurodegenerative and psychiatric disorders. Front. Neurosci., 2023, 17, 1092537.
[http://dx.doi.org/10.3389/fnins.2023.1092537] [PMID: 36875655]
[15]
Alam, M.; Mayerhofer, A.; Schmidt, W.J. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Behav. Brain Res., 2004, 151(1-2), 117-124.
[http://dx.doi.org/10.1016/j.bbr.2003.08.014] [PMID: 15084427]
[16]
Cannon, J.R.; Tapias, V.; Na, H.M.; Honick, A.S.; Drolet, R.E.; Greenamyre, J.T. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol. Dis., 2009, 34(2), 279-290.
[http://dx.doi.org/10.1016/j.nbd.2009.01.016] [PMID: 19385059]
[17]
Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci., 2000, 3(12), 1301-1306.
[http://dx.doi.org/10.1038/81834] [PMID: 11100151]
[18]
Sanfeliu, C.; Bartra, C.; Suñol, C.; Rodríguez-Farré, E. New insights in animal models of neurotoxicity-induced neurodegeneration. Front. Neurosci., 2024, 17, 1248727.
[http://dx.doi.org/10.3389/fnins.2023.1248727] [PMID: 38260026]
[19]
Saravanan, K.S.; Sindhu, K.M.; Senthilkumar, K.S.; Mohanakumar, K.P. l-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem. Int., 2006, 49(1), 28-40.
[http://dx.doi.org/10.1016/j.neuint.2005.12.016] [PMID: 16490285]
[20]
Ren, Y.; Liu, W.; Jiang, H.; Jiang, Q.; Feng, J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem., 2005, 280(40), 34105-34112.
[http://dx.doi.org/10.1074/jbc.M503483200] [PMID: 16091364]
[21]
Swarnkar, S.; Singh, S.; Mathur, R.; Patro, I.K.; Nath, C. A study to correlate rotenone induced biochemical changes and cerebral damage in brain areas with neuromuscular coordination in rats. Toxicology, 2010, 272(1-3), 17-22.
[http://dx.doi.org/10.1016/j.tox.2010.03.019] [PMID: 20371261]
[22]
Chuproski, A.P.; Azevedo, E.M.; Ilkiw, J.; Miloch, J.; Lima, M.M.S. Metabolic dysfunctions in the intranigral rotenone model of Parkinson’s disease. Exp. Brain Res., 2023, 241(5), 1289-1298.
[http://dx.doi.org/10.1007/s00221-023-06605-w] [PMID: 37000202]
[23]
Verma, R.; Nehru, B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson’s disease. Neurochem. Int., 2009, 55(6), 369-375.
[http://dx.doi.org/10.1016/j.neuint.2009.04.001] [PMID: 19375462]
[24]
Nehru, B.; Verma, R.; Khanna, P.; Sharma, S.K. Behavioral alterations in rotenone model of Parkinson’s disease: Attenuation by co-treatment of centrophenoxine. Brain Res., 2008, 1201, 122-127.
[http://dx.doi.org/10.1016/j.brainres.2008.01.074] [PMID: 18308296]
[25]
Khurana, N.; Gajbhiye, A. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson’s disease. Neurotoxicology, 2013, 39, 57-64.
[http://dx.doi.org/10.1016/j.neuro.2013.08.005] [PMID: 23994302]
[26]
Ingale, S.P.; Kasture, S.B. Antioxidant and antiparkinsonian activity of Passiflora incarnata leaves. Orient. Pharm. Exp. Med., 2014, 14(3), 231-236.
[http://dx.doi.org/10.1007/s13596-014-0149-3]
[27]
Singh, A.; Gupta, A.; Mishra, A.; Gupta, V.; Bansal, P.; Kumar, S. Medicinal plant for curing Alzheimer’s disease. Int. J. Pharm. Biol. Arch., 2010, 1(2), 108-114.
[28]
Craig, S.A.S. Betaine in human nutrition. Am. J. Clin. Nutr., 2004, 80(3), 539-549.
[http://dx.doi.org/10.1093/ajcn/80.3.539] [PMID: 15321791]
[29]
Akhavan-Salamat, H.; Ghasemi, H.A. Alleviation of chronic heat stress in broilers by dietary supplementation of betaine and turmeric rhizome powder: Dynamics of performance, leukocyte profile, humoral immunity, and antioxidant status. Trop. Anim. Health Prod., 2016, 48(1), 181-188.
[http://dx.doi.org/10.1007/s11250-015-0941-1] [PMID: 26494545]
[30]
Alirezaei, M.; Gheisari, H.R.; Ranjbar, V.R.; Hajibemani, A. Betaine: A promising antioxidant agent for enhancement of broiler meat quality. Br. Poult. Sci., 2012, 53(5), 699-707.
[http://dx.doi.org/10.1080/00071668.2012.728283] [PMID: 23281766]
[31]
Alirezaei, M.; Jelodar, G.; Ghayemi, Z.; Mehr, M.K. Antioxidant and methyl donor effects of betaine versus ethanol-induced oxidative stress in the rat liver. Comp. Clin. Pathol., 2014, 23(1), 161-168.
[http://dx.doi.org/10.1007/s00580-012-1589-0]
[32]
Alirezaei, M.; Khoshdel, Z.; Dezfoulian, O.; Rashidipour, M.; Taghadosi, V. Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats. J. Physiol. Sci., 2015, 65(3), 243-252.
[http://dx.doi.org/10.1007/s12576-015-0360-0] [PMID: 25665954]
[33]
Ahn, M.; Kang, Y.; Moon, J.; Kim, S.; Moon, C.; Shin, T. Oral administration of betaine ameliorates ethanol-induced gastric injury in rats through its antioxidant effects. Orient. Pharm. Exp. Med., 2014, 14(3), 237-243.
[http://dx.doi.org/10.1007/s13596-014-0158-2]
[34]
Zhao, G.; He, F.; Wu, C.; Li, P.; Li, N.; Deng, J.; Zhu, G.; Ren, W.; Peng, Y. Betaine in Inflammation: Mechanistic Aspects and Applications. Front. Immunol., 2018, 9, 1070.
[http://dx.doi.org/10.3389/fimmu.2018.01070] [PMID: 29881379]
[35]
Sorgun, O.; Çakır, A.; Bora, E.S.; Erdoğan, M.A.; Uyanıkgil, Y.; Erbaş, O. Anti-inflammatory and antioxidant properties of betaine protect against sepsis-induced acute lung injury: CT and histological evidence. Braz. J. Med. Biol. Res., 2023, 56, e12906.
[http://dx.doi.org/10.1590/1414-431x2023e12906] [PMID: 37970921]
[36]
Carter, R.J.; Morton, J.; Dunnett, S.B. Motor coordination and balance in rodents. Current Protocols. In: Neuroscience; Wiley: Hoboken, New Jersey, 2001.
[http://dx.doi.org/10.1002/0471142301.ns0812s15]
[37]
Costall, B.; Naylor, R.J. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacology (Berl.), 1974, 34(3), 233-241.
[http://dx.doi.org/10.1007/BF00421964] [PMID: 4594816]
[38]
Ludolph, A.C.; He, F.; Spencer, P.S.; Hammerstad, J.; Sabri, M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci., 1991, 18(4), 492-498.
[39]
Giraldo, G.; Brooks, M.; Giasson, B.I.; Janus, C. Locomotor differences in mice expressing wild-type human α-synuclein. Neurobiol. Aging, 2018, 65, 140-148.
[http://dx.doi.org/10.1016/j.neurobiolaging.2018.01.020] [PMID: 29477894]
[40]
Khurana, N.; Ishar, M.P.S.; Gajbhiye, A.; Goel, R.K. PASS assisted prediction and pharmacological evaluation of novel nicotinic analogs for nootropic activity in mice. Eur. J. Pharmacol., 2011, 662(1-3), 22-30.
[http://dx.doi.org/10.1016/j.ejphar.2011.04.048] [PMID: 21554868]
[41]
Tapias, V.; Cannon, J.R.; Greenamyre, J.T. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson’s disease model. J. Neurosci. Res., 2010, 88(2), 420-427.
[http://dx.doi.org/10.1002/jnr.22201] [PMID: 19681169]
[42]
Kumar, V. Potential medicinal plants for CNS disorders: An overview. Phytother. Res., 2006, 20(12), 1023-1035.
[http://dx.doi.org/10.1002/ptr.1970] [PMID: 16909441]
[43]
Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 1979, 95(2), 351-358.
[http://dx.doi.org/10.1016/0003-2697(79)90738-3] [PMID: 36810]
[44]
Beutler, E.; Duron, O.; Kelly, B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med., 1963, 61, 882-888.
[PMID: 13967893]
[45]
Aebi, H. Methods. In: Enzymatic Analysis; Academic press: New York, 1974.
[46]
Di Wang, H.; Pagano, P.J.; Du, Y.; Cayatte, A.J.; Quinn, M.T.; Brecher, P.; Cohen, R.A. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ. Res., 1998, 82(7), 810-818.
[http://dx.doi.org/10.1161/01.RES.82.7.810] [PMID: 9562441]
[47]
Singh, A.P.; Singh, M.; Balakumar, P. Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J. Cardiovasc. Pharmacol., 2008, 51(6), 596-604.
[http://dx.doi.org/10.1097/FJC.0b013e31817ae60f] [PMID: 18520950]
[48]
Sharma, N.; Bafna, P. Effect of Cynodon dactylon on rotenone induced Parkinson’s disease. Orient. Pharm. Exp. Med., 2012, 12(3), 167-175.
[http://dx.doi.org/10.1007/s13596-012-0075-1]
[49]
Davinelli, S.; Maes, M.; Corbi, G.; Zarrelli, A.; Willcox, DC.; Scapagnini, G. Dietary phytochemicals and neuro-inflammaging: From mechanistic insights to translational challenges. Immun. Ageing, 2016, 13(3), 16.
[http://dx.doi.org/10.1186/s12979-016-0070-3]
[50]
Bharwana, S.A.; Ali, S.; Farooq, M.A.; Iqbal, N.; Hameed, A.; Abbas, F.; Ahmad, M.S.A. Glycine betaine-induced lead toxicity tolerance related to elevated photosynthesis, antioxidant enzymes suppressed lead uptake and oxidative stress in cotton. Turk. J. Bot., 2014, 38(2), 281-292.
[http://dx.doi.org/10.3906/bot-1304-65]
[51]
Osman, H.S. Enhancing antioxidant–yield relationship of pea plant under drought at different growth stages by exogenously applied glycine betaine and proline. Ann. Agric. Sci., 2015, 60(2), 389-402.
[http://dx.doi.org/10.1016/j.aoas.2015.10.004]
[52]
Choi, Y.; Jung, K.; Kim, H.J.; Chun, J.; Ahn, M.; Jee, Y.; Ko, H.J.; Moon, C.; Matsuda, H.; Tanaka, A.; Kim, J.; Shin, T. Attenuation of Experimental Autoimmune Uveitis in Lewis Rats by Betaine. Exp. Neurobiol., 2021, 30(4), 308-317.
[http://dx.doi.org/10.5607/en21011] [PMID: 34483144]
[53]
Makhija, D.T.; Jagtap, A.G.; Deshpande, J.V.; Shankaranarayanan, J.; Kulkarni, S.K. Nutritional supplement of lutein attenuates dopaminergic neurodegeneration induced by rotenone in rats. PharmaNutrition, 2014, 2(3), 95-96.
[http://dx.doi.org/10.1016/j.phanu.2013.11.058]
[54]
Dexter, D.T.; Holley, A.E.; Flitter, W.D.; Slater, T.F.; Wells, F.R.; Daniel, S.E.; Lees, A.J.; Jenner, P.; Marsden, C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study. Mov. Disord., 1994, 9(1), 92-97.
[http://dx.doi.org/10.1002/mds.870090115] [PMID: 8139611]
[55]
Al-Quraishy, S.; Dkhil, M.A.; Abdel Moneim, A.E. Protective effects of Portulaca oleracea against rotenone mediated depletion of glutathione in the striatum of rats as an animal model of Parkinson’s disease. Pestic. Biochem. Physiol., 2012, 103(2), 108-114.
[http://dx.doi.org/10.1016/j.pestbp.2012.04.005]
[56]
Chance, B.; Sies, H.; Boveris, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev., 1979, 59(3), 527-605.
[http://dx.doi.org/10.1152/physrev.1979.59.3.527] [PMID: 37532]
[57]
Jin, Z.; Mendu, S.K.; Birnir, B. GABA is an effective immunomodulatory molecule. Amino Acids, 2013, 45(1), 87-94.
[http://dx.doi.org/10.1007/s00726-011-1193-7] [PMID: 22160261]
[58]
Nunomura, A.; Moreira, P.I.; Castellani, R.J.; Lee, H.; Zhu, X.; Smith, M.A.; Perry, G. Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox. Res., 2012, 22(3), 231-248.
[http://dx.doi.org/10.1007/s12640-012-9331-x] [PMID: 22669748]
[59]
Alirezaei, M. Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats. Iran. J. Basic Med. Sci., 2015, 18(10), 950-957.
[PMID: 26730328]
[60]
Lawson-Yuen, A.; Levy, H.L. The use of betaine in the treatment of elevated homocysteine. Mol. Genet. Metab., 2006, 88(3), 201-207.
[http://dx.doi.org/10.1016/j.ymgme.2006.02.004] [PMID: 16545978]

Rights & Permissions Print Cite